IBB - The Best ETF To Play Biotech
The recently announced deal of Bristol-Myers Squibb (BMY) acquiring Celgene (CELG) got me thinking about biotech & big pharma stocks. The following chart perfectly sums up why I believe big pharma will continue to be acquirers of large-cap biotech companies and small/mid cap companies. Slowing growth due to generic competition and increased scrutiny of drug prices has caused shares of big pharma companies to underperform biotechs and the overall healthcare sector. As you can see below, big pharma as represented by the SPDR S&P Pharmaceuticals ETF (XPH), has gone